The excitement surrounding Viking Therapeutics (NASDAQ: VKTX) stock has been dying down significantly lately. In six months, the stock has lost more than 40% of its value. Many investors may have ...

Shares of Viking Therapeutics have fallen by more than half since the stock peaked early last year. Viking Therapeutics is developing a drug that might be able to outperform today's most popular ...

And with a growing number of companies in the GLP-1 space, investors may be losing interest in the stock. Could Viking's rapidly declining valuation be a sign that the bubble has burst for it ...

Viking Therapeutics' weight management candidate could produce blockbuster sales down the road, but this isn't enough to hold the attention of a stock market obsessed with artificial intelligence ...

Wednesday, Goldman Sachs initiated coverage on Viking Holdings (NYSE:VIK) stock, a $20.9 billion market cap cruise operator, with a Neutral rating and a 12-month price target of $49.00. The firm's ...

It's been a volatile year for Viking Therapeutics stock, though good news on the weight-loss-drug front has the healthcare stock up 260% since the start of January. And Wall Street sees even more ...